首页|PI3K-AKT信号通路调控慢阻肺气道重塑及中药干预作用研究新进展

PI3K-AKT信号通路调控慢阻肺气道重塑及中药干预作用研究新进展

扫码查看
原文链接
  • NETL
  • NSTL
  • 万方数据
慢性阻塞性肺疾病(COPD)简称慢阻肺,是一种以渐进性且不完全可逆的肺气流阻塞为特征的慢性气道炎症性疾病,炎症引起的以组织增生为主的气道重塑是慢阻肺疾病过程中的肺组织病理学基础,也是引起慢阻肺气流受限的关键因素.近年来,大量研究证实磷酯酰肌醇3激酶(PI3K)/蛋白激酶B(AKT)信号通路可通过调控上皮间充质转化(EMT)、基质金属蛋白酶(MMPs)、哺乳动物雷帕霉素靶蛋白(mTOR)、表皮生长因子受体(EGFR)以及核因子-κB(NF-κB)等而参与慢阻肺气道重塑.中医药在治疗慢阻肺等慢性复杂性疾病过程中有明显的优势,而调节PI3K/AKT信号通路是其防治慢阻肺的作用机制之一,但目前国内外对该领域系统性回顾及总结较少.基于此,本文就近年来PI3K/AKT信号通路参与慢阻肺气道重塑的调控机制及中药干预作用进行综述,以期为慢阻肺的基础研究与新药研发提供理论依据.
Traditional Chinese Medicine Regulates Airway Remodeling of Chronic Obstructive Pulmonary Disease via PI3K-AKT Signaling Pathway:a Review
Chronic obstructive pulmonary disease(COPD)is a chronic airway inflammatory disease characterized by progressive and incompletely.reversible pulmonary airflow obstruction.Airway remodeling induced by chronic inflammation,which is mainly caused by tissue proliferation,is the histopathological basis and a key factor causing airflow limitation in COPD.Phosphoinositol-3-kinase(PI3K)/protein kinase B(AKT)signaling pathway is involved in airway remodeling in COPD by regulating epithelial-mesenchymal transition(EMT),epidermal growth factor receptor(EGFR),nuclear factor-κB(NF-κB),mammalian target of rapamycin(mTOR),and matrix metalloproteinases(MMPs).Tradition-al Chinese medicine has obvious advantages in the treatment of chronic and complex diseases such as COPD,and the regulation of PI3K/AKT signaling pathway is one of the mechanisms of the prevention and treatment of COPD.However,there are few systematic reviews and conclu-sions in this field at home and abroad.This article reviews the research progress in the regulatory mechanism of PI3K/AKT signaling pathway involved in airway remodeling in COPD and the intervention effect of traditional Chinese medicine,aiming to provide a theoretical basis for the fundamental research and drug development for COPD.

Chronic obstructive pulmonary diseaseAirway remodelingPI3K-AKT signaling pathwayRegulatory mechanismTraditional Chinese medicine

梁可克、王志旺、黄柯婷、赵跃、李济阳、杜玥、席建宏

展开 >

甘肃中医药大学药学院,兰州 730000

陇药产业创新研究院,兰州 730000

慢阻肺 气道重塑 磷酯酰肌醇3激酶/蛋白激酶B 信号通路 调控机制 中药

国家自然科学基金国家自然科学基金甘肃省自然科学基金甘肃省自然科学基金甘肃省自然科学基金

822608528146066820JR5RA1831606RJZA0111310RJZA086

2024

中药药理与临床
中国药理学会 四川省中医药科学院

中药药理与临床

北大核心
影响因子：0.996
ISSN：1001-859X
年,卷(期)：2024.40(5)